Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Co-Delivery of Cisplatin and Curcumin Using Mesoporous Silica Nanoparticles to Improve their Anticancer Effects

Author(s): Solmaz Maleki Dizaj, Seyyedeh Saba Bolouri Ebrahimi, Sadaf Jafari, Anita Basiri, Javad Yazdani, Simin Sharifi* and Elaheh Dalir Abdolahinia*

Volume 11, Issue 4, 2023

Published on: 11 May, 2023

Page: [364 - 372] Pages: 9

DOI: 10.2174/2211738511666230327123627

Price: $65

Abstract

Aims: This study aimed to prepare and evaluate the physicochemical and anticancer properties of cisplatin and curcumin-loaded mesoporous silica nanoparticles (Cis-Cur-MSNs).

Background: In recent years, combination treatment has attained better outcomes than monotherapy in oncology. Cis-Cur-MSNs were prepared by precipitation technique.

Objective: The objective of the present study was the evaluation of the physicochemical and anticancer properties of cisplatin and curcumin-loaded mesoporous silica nanoparticles (Cis-Cur-MSNs).

Methods: The prepared materials were assessed in terms of physicochemical methods. The drug release pattern from the MSNs was also evaluated via ultraviolet spectrophotometry. In addition, the porosity and surface area of prepared nanoparticles were determined using the Brunauer-Emmett-Teller (BET) technique. The cytotoxicity of Cis-Cur-MSNs was evaluated on the HN5 cells as head and neck squamous carcinoma cell lines. Furthermore, ROS production of Cis-Cur-MSNs treated cells was evaluated compared with untreated cells.

Results: According to the results, prepared nanoparticles displayed nanometer size, rod morphology, and negative surface charge with mesoporous structure belonging to the MCM-41 family (twodimensional hexagonal). Regarding the results of BET adsorption and desorption isotherm analysis for Cis-Cur-MSNs and drug-free MSNs, pore diameter, pore volume, specific surface area, and drug-loaded pore area in MSNs were decreased. In the first 10 days, the prepared nanoparticles exhibited a relatively rapid release pattern for cisplatin and curcumin, and until the 35th day, the release of them from the MSNs continued slowly.

Conclusion: The cytotoxic effect of Cis-Cur-MSNs was significantly more than Cur-MSNs and Cis- MSNs in 24 and 48 h incubation time (p < 0.05). The results suggest that Cis-Cur-MSNs may be beneficial in the development of a cancer treatment protocol.

Others: The prepared nanoparticle in the present study could be a potential biomaterial for cancer treatment.

« Previous Next »
Graphical Abstract

[1]
Mohseni M, Samadi N, Ghanbari P, et al. Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance. Iran J Basic Med Sci 2016; 19(3): 300.
[2]
Lin SR, Fu YS, Tsai MJ, Cheng H, Weng CF. Natural compounds from herbs that can potentially execute as autophagy inducers for cancer therapy. Int J Mol Sci 2017; 18(7): 1412.
[http://dx.doi.org/10.3390/ijms18071412]
[3]
Samadi N, Ghanbari P, Mohseni M, et al. Combination therapy increases the efficacy of docetaxel, vinblastine and tamoxifen in cancer cells. J Cancer Res Ther 2014; 10(3): 715.
[http://dx.doi.org/10.4103/0973-1482.139152]
[4]
Armat M, Bakhshaiesh TO, Sabzichi M, et al. The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line. Bosn J Basic Med Sci 2016; 16(1): 28.
[http://dx.doi.org/10.17305/bjbms.2016.674]
[5]
Samadi N, Saei AA, Sharifi S, et al. Sphingosin 1-phosphate contributes in tumor progression. J Cancer Res Ther 2013; 9(4): 556.
[http://dx.doi.org/10.4103/0973-1482.126446]
[6]
Bakhshaiesh TO, Armat M, Shanehbandi D, et al. Arsenic trioxide promotes paclitaxel cytotoxicity in resistant breast cancer cells. Asian Pac J Cancer Prev 2015; 16(13): 5191-7.
[http://dx.doi.org/10.7314/APJCP.2015.16.13.5191]
[7]
Montané X, Kowalczyk O, Reig-Vano B, et al. Current perspectives of the applications of polyphenols and flavonoids in cancer therapy. Molecules 2020; 25(15): 3342.
[http://dx.doi.org/10.3390/molecules25153342]
[8]
Sheikh I, Sharma V, Tuli HS, et al. Cancer chemoprevention by flavonoids, dietary polyphenols and terpenoids. Biointerface Res Appl Chem 2020; 11(1): 8502-37.
[http://dx.doi.org/10.33263/BRIAC111.85028537]
[9]
Maleki DS, Alipour M, Dalir AE, et al. Curcumin nanoformulations: Beneficial nanomedicine against cancer. Phytother Res 2022; 36(3): 1156-81.
[http://dx.doi.org/10.1002/ptr.7389]
[10]
Sharifi S, Zununi VS, Ahmadian E, et al. Stem cell therapy: Curcumin does the trick. Phytother Res 2019; 33(11): 2927-37.
[http://dx.doi.org/10.1002/ptr.6482]
[11]
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 2018; 378(22): 2078-92.
[http://dx.doi.org/10.1056/NEJMoa1801005]
[12]
Sharifi S, Dalir AE, Maleki Dizaj S, et al. Preparation, the physicochemical assessment, and the cytotoxicity of Cisplatin-loaded mesoporous Silica nanoparticles against head and neck squamous cell carcinoma cell line. Int J Nanodimens 2022; 13(3): 320-8.
[http://dx.doi.org/10.22034/IJND.2022.1954488.2125]
[13]
Li S, Wu Y, Ding Y, Yu M, Ai Z. CerS6 regulates cisplatin resistance in oral squamous cell carcinoma by altering mitochondrial fission and autophagy. J Cell Physiol 2018; 233(12): 9416-25.
[http://dx.doi.org/10.1002/jcp.26815]
[14]
Acklin S, Xia F. The role of nucleotide excision repair in cisplatin-induced peripheral neuropathy: Mechanism, prevention, and treatment. Int J Mol Sci 2021; 22(4): 1975.
[http://dx.doi.org/10.3390/ijms22041975]
[15]
Zhang XK, Wang QW, Xu YJ, Sun HM, Wang L, Zhang LX. Co‐delivery of cisplatin and oleanolic acid by silica nanoparticles‐enhanced apoptosis and reverse multidrug resistance in lung cancer. Kaohsiung J Med Sci 2021; 37(6): 505-12.
[http://dx.doi.org/10.1002/kjm2.12365]
[16]
Chen R, Chen Q, Qin H, Xing D. A photoacoustic shockwave triggers the size shrinkage of nanoparticles to obviously improve tumor penetration and therapeutic efficacy. Nanoscale 2019; 11(3): 1423-36.
[http://dx.doi.org/10.1039/C8NR08271E]
[17]
Khan MM, Madni A, Tahir N, et al. Co-delivery of curcumin and cisplatin to enhance cytotoxicity of cisplatin using lipid-chitosan hybrid nanoparticles. Int J Nanomedicine 2020; 15: 2207-17.
[http://dx.doi.org/10.2147/IJN.S247893]
[18]
Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res 2010; 3(1): 11.
[http://dx.doi.org/10.1186/1757-2215-3-11]
[19]
Kuhad A, Pilkhwal S, Sharma S, Tirkey N, Chopra K. Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem 2007; 55(25): 10150-5.
[http://dx.doi.org/10.1021/jf0723965]
[20]
Youm I, West MB, Li W, Du X, Ewert DL, Kopke RD. siRNA-loaded biodegradable nanocarriers for therapeutic MAPK1 silencing against cisplatin-induced ototoxicity. Int J Pharm 2017; 528(1-2): 611-23.
[http://dx.doi.org/10.1016/j.ijpharm.2017.06.035]
[21]
Zhang J, Liu J, Xu X, Li L. Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer. Cancer Chemother Pharmacol 2017; 79(3): 479-87.
[http://dx.doi.org/10.1007/s00280-017-3238-4]
[22]
Hussain Y, Islam L, Khan H, Filosa R, Aschner M, Javed S. Curcumin–cisplatin chemotherapy: A novel strategy in promoting chemotherapy efficacy and reducing side effects. Phytother Res 2021; 35(12): 6514-29.
[http://dx.doi.org/10.1002/ptr.7225]
[23]
Abadi AJ, Mirzaei S, Mahabady MK, et al. Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects. Phytother Res 2022; 36(1): 189-213.
[http://dx.doi.org/10.1002/ptr.7305]
[24]
Batra H, Pawar S, Bahl D. Curcumin in combination with anti-cancer drugs: A nanomedicine review. Pharmacol Res 2019; 139: 91-105.
[http://dx.doi.org/10.1016/j.phrs.2018.11.005]
[25]
Shevtsov M, Multhoff G, Mikhaylova E, Shibata A, Guzhova I, Margulis B. Combination of anti-cancer drugs with molecular chaperone inhibitors. Int J Mol Sci 2019; 20(21): 5284.
[http://dx.doi.org/10.3390/ijms20215284]
[26]
Kang S, Kang K, Chae A, Kim YK, Jang H, Min DH. Fucoidan-coated coral-like Pt nanoparticles for computed tomography-guided highly enhanced synergistic anticancer effect against drug-resistant breast cancer cells. Nanoscale 2019; 11(32): 15173-83.
[http://dx.doi.org/10.1039/C9NR04495G]
[27]
Xiao Y, Liu J, Guo M, et al. Synergistic combination chemotherapy using carrier-free celastrol and doxorubicin nanocrystals for overcoming drug resistance. Nanoscale 2018; 10(26): 12639-49.
[http://dx.doi.org/10.1039/C8NR02700E]
[28]
Li D, Cui R, Xu S, Liu Y. Synergism of cisplatin-oleanolic acid co-loaded hybrid nanoparticles on gastric carcinoma cells for enhanced apoptosis and reversed multidrug resistance. Drug Deliv 2020; 27(1): 191-9.
[http://dx.doi.org/10.1080/10717544.2019.1710622]
[29]
Zhu Y, Yu F, Tan Y, et al. Reversing activity of cancer associated fibroblast for staged glycolipid micelles against internal breast tumor cells. Theranostics 2019; 9(23): 6764-79.
[http://dx.doi.org/10.7150/thno.36334]
[30]
Li Z, Zhang Y, Feng N. Mesoporous silica nanoparticles: Synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery. Expert Opin Drug Deliv 2019; 16(3): 219-37.
[http://dx.doi.org/10.1080/17425247.2019.1575806]
[31]
Argyo C, Weiss V, Bräuchle C, Bein T. Multifunctional mesoporous silica nanoparticles as a universal platform for drug delivery. Chem Mater 2014; 26(1): 435-51.
[http://dx.doi.org/10.1021/cm402592t]
[32]
Alyassin Y, Sayed EG, Mehta P, et al. Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents. Drug Discov Today 2020; 25(8): 1513-20.
[http://dx.doi.org/10.1016/j.drudis.2020.06.006]
[33]
Maleki Dizaj S, Sharifi S, Tavakoli F, et al. Curcumin-loaded silica nanoparticles: Applications in infectious disease and food industry. Nanomaterials 2022; 12(16): 2848.
[http://dx.doi.org/10.3390/nano12162848]
[34]
Memar MY, Yekani M, Ghanbari H, et al. Antimicrobial and antibiofilm activities of meropenem loaded-mesoporous silica nanoparticles against carbapenem-resistant Pseudomonas aeruginosa. J Biomater Appl 2021; 36(4): 605-12.
[http://dx.doi.org/10.1177/08853282211003848]
[35]
Freidus LG, Kumar P, Marimuthu T, Pradeep P, Choonara YE. Theranostic mesoporous silica nanoparticles loaded with a curcumin-naphthoquinone conjugate for potential cancer intervention. Front Mol Biosci 2021; 8: 670792.
[http://dx.doi.org/10.3389/fmolb.2021.670792]
[36]
Memar MY, Yekani M, Ghanbari H, Shahi S, Sharifi S, Maleki Dizaj S. Biocompatibility, cytotoxicity and antibacterial effects of meropenem-loaded mesoporous silica nanoparticles against carbapenem-resistant Enterobacteriaceae. Artif Cells Nanomed Biotechnol 2020; 48(1): 1354-61.
[http://dx.doi.org/10.1080/21691401.2020.1850466]
[37]
Sharifi S, Dalir Abdolahinia E, Ghavimi MA, et al. Effect of curcumin-loaded mesoporous silica nanoparticles on the head and neck cancer cell line, HN5. Curr Issues Mol Biol 2022; 44(11): 5247-59.
[http://dx.doi.org/10.3390/cimb44110357]
[38]
Maleki Dizaj S, Lotfipour F, Barzegar-Jalali M, Zarrintan M-H. Adibkia KJAc. Application of box–behnken design to prepare gentamicin-loaded calcium carbonate nanoparticles. Artif Cells Nanomed Biotechnol 2016; 44(6): 1475-81.
[http://dx.doi.org/10.3109/21691401.2015.1042108]
[39]
Maleki Dizaj S, Lotfipour F, Barzegar-Jalali M, Zarrintan M-H. Adibkia KJAc. Ciprofloxacin HCl-loaded calcium carbonate nanoparticles: preparation, solid state characterization, and evaluation of antimicrobial effect against Staphylococcus aureus. Artif Cells Nanomed Biotechnol 2017; 45(3): 535-43.
[http://dx.doi.org/10.3109/21691401.2016.1161637]
[40]
Zhao Y, Wang Y, Ran F, et al. A comparison between sphere and rod nanoparticles regarding their in vivo biological behavior and pharmacokinetics. Scientific Reports 2017; 7(1): 1-11.
[http://dx.doi.org/10.1038/s41598-017-03834-2]
[41]
Karimzadeh M, Rashidi L. Ganji FJDd. Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells. Drug Dev Ind Pharm 2017; 43(4): 628-36.
[http://dx.doi.org/10.1080/03639045.2016.1275668]
[42]
Cheng Y, Zhao P, Wu S, et al. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma. Int J Pharm 2018; 545(1-2): 261-73.
[http://dx.doi.org/10.1016/j.ijpharm.2018.05.007]
[43]
Baharuddin P, Satar N, Fakiruddin KS, et al. Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines. Oncol Rep 2016; 35(1): 13-25.
[http://dx.doi.org/10.3892/or.2015.4371]
[44]
Mori H, Niwa K, Zheng Q, Yamada Y, Sakata K, Yoshimi N. Cell proliferation in cancer prevention; effects of preventive agents on estrogen-related endometrial carcinogenesis model and on an in vitro model in human colorectal cells. Mutat Res 2001; 480-481: 201-7.
[http://dx.doi.org/10.1016/S0027-5107(01)00200-7]
[45]
Zhang Y, Dai M, Yuan Z. Methods for the detection of reactive oxygen species. Anal Methods 2018; 10(38): 4625-38.
[http://dx.doi.org/10.1039/C8AY01339J]
[46]
Raj L, Ide T, Gurkar AU, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011; 475(7355): 231-4.
[http://dx.doi.org/10.1038/nature10167]
[47]
Gilardini Montani MS, Santarelli R, Granato M, et al. EBV reduces autophagy, intracellular ROS and mitochondria to impair monocyte survival and differentiation. Autophagy 2019; 15(4): 652-67.
[http://dx.doi.org/10.1080/15548627.2018.1536530]
[48]
Wang T, Wu X. Al rudaisat M, Song Y, Cheng H. Curcumin induces G2/M arrest and triggers autophagy, ROS generation and cell senescence in cervical cancer cells. J Cancer 2020; 11(22): 6704-15.
[http://dx.doi.org/10.7150/jca.45176]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy